This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Viral Infections  • Drug Therapy  • Adverse Effects  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Significant Progress But Not the Final Step

Michael P. Manns, MD; Heiner Wedemeyer, MD

JAMA. 2004;292:2909-2913.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the modern era of highly active antiretroviral therapy (HAART), hepatitis C virus (HCV) has emerged as a major cause of morbidity and death in human immunodeficiency virus (HIV) infection. An estimated 15% to 30% of HIV-infected individuals are coinfected with HCV, representing 150 000 to 300 000 patients in the United States alone.¹ The prevalence of anti-HCV antibodies in HIV-infected persons differs significantly according to the HIV-exposure risk category, ranging from less than 10% in homosexual men to more than 85% in injecting drug users.¹ In the vast majority of immunocompetent non–HIV-infected persons, chronic hepatitis C usually takes a relatively mild course, leading to liver cirrhosis in 2% to 25% after 20 to 25 years depending on the individual risk factor profile.^2-3 Liver-related death is only slightly more frequent in HCV-infected individuals.⁴ In contrast, hepatitis C may take a much more severe course in . . . [Full Text of this Article]

Author Affiliations: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients: A Randomized Controlled Trial
, , , , , , , , , , , , , , and
JAMA. ;292():2839-2848.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treating viral hepatitis C: efficacy, side effects, and complications.
Manns et al.
Gut 2006;55:1350-1359.
FULL TEXT  

Treatment of Hepatitis C in HIV-Coinfected Patients
Hughes and Shafran
The Annals of Pharmacotherapy 2006;40:479-489.
ABSTRACT | FULL TEXT  

Management of Hepatitis C Infection in the HIV-Infected Patient
McNelis
Journal of Pharmacy Practice 2006;19:37-52.
ABSTRACT